Investors Urged to Take Action as Pomerantz Law Firm Investigates EyePoint, Inc.

The Pomerantz Law Firm has initiated an investigation into claims concerning investors of EyePoint, Inc. (NASDAQ: EYPT). This development comes in the wake of significant stock price fluctuations linked to the company’s announcement of clinical trial results for its treatment, DURAVYU™. Investors who suspect they have suffered losses due to potential securities fraud are encouraged to reach out to the firm for support.

On August 17, 2026, EyePoint released its topline results from the LUGANO Phase 3 clinical trial of DURAVYU™. Unfortunately, the data revealed that the study did not meet its primary endpoint regarding improvement in visual acuity compared to a benchmark treatment, aflibercept. As a direct result of this disappointing announcement, EyePoint's stock plummeted by nearly 67%, closing at $4.87 per share on the same day. This sharp decline has raised serious concerns among shareholders about whether the company's executives misled them regarding the efficacy of their treatment or positioned their business unlawfully.

Pomerantz LLP, based in New York with additional offices in major cities around the world, is well-known for its focus on corporate, securities, and antitrust class action litigation. It specializes in representing the rights of investors who face injustices due to securities fraud and corporate misbehavior. Founded by Abraham L. Pomerantz, the firm has a legacy of fighting for victims’ rights, and it has successfully recovered numerous significant settlements for its clients over its over 80 years of operation.

The firm is calling on EyePoint investors to potentially join a class action lawsuit if they feel impacted by these recent events. For those who wish to participate, they can contact Danielle Peyton at Pomerantz via email at [email protected] or call at 646-581-9980, extension 7980. Legal actions of this nature can play a crucial role in holding corporations accountable for their actions, especially in cases where investors may have been misled.

The current situation at EyePoint reflects broader concerns about transparency and integrity within the biotech industry, where the stakes surrounding clinical trials can significantly impact stock valuations and public perception. As such, investors must stay informed and vigilant about the developments surrounding their investments and available legal recourse. With the help of firms like Pomerantz, those affected by potential securities fraud can seek the justice they deserve.

Pomerantz emphasizes that past results do not guarantee future outcomes, reminding investors that they need to evaluate their individual circumstances and potential claims carefully. For EyePoint investors, this is an opportune moment to consider action and ensure their rights and interests are adequately protected moving forward.